Veru Completes Enrollment for Second Part of Phase 1/2 VERU-111 Trial
News
Veru has completed enrollment for the second portion of a Phase 1/2 study of VERU-111, its investigational therapy for men with metastatic castration-resistant prostate cancer (mCRPC) who failed to respond ... Read more